Selpercatinib
Sign in to save this workspacePrimary targets: RET · FDA status: FDA Approved
Selectivity scorecard
KISS
96.72
Gini
0.635
CATDS
0.013
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Selpercatinib. Strongest target: RET at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RET | 100.0% | 0.0% |
| 2 | FLT4_VEGFR3 | 98.9% | 1.1% |
| 3 | C_KIT | 98.7% | 1.3% |
| 4 | FLT1_VEGFR1 | 96.2% | 3.8% |
| 5 | FLT3 | 96.1% | 3.9% |
| 6 | KDR_VEGFR2 | 95.9% | 4.1% |
| 7 | FGFR2 | 95.0% | 5.0% |
| 8 | JAK2 | 93.8% | 6.2% |
| 9 | EPHB1 | 93.6% | 6.4% |
| 10 | EPHA6 | 93.0% | 7.0% |
| 11 | FMS | 92.8% | 7.2% |
| 12 | DDR2 | 92.2% | 7.8% |
| 13 | AURORA_C | 90.4% | 9.6% |
| 14 | PLK4_SAK | 89.2% | 10.8% |
| 15 | FGFR1 | 87.4% | 12.6% |
| 16 | LCK | 87.3% | 12.7% |
| 17 | FGFR3 | 86.6% | 13.4% |
| 18 | LYN | 86.4% | 13.6% |
| 19 | CHK2 | 86.3% | 13.7% |
| 20 | AURORA_B | 86.1% | 13.9% |
Selectivity landscape
Where Selpercatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Selpercatinib.
Annotations
Sign in to read and post annotations.
Loading…